tlas Antibodies: Atlas Antibodies was founded in 2006 by
researchers at the Royal Institute of Technology (KTH) in Stockholm and the
Rudbeck Laboratory, Uppsala University in Uppsala, Sweden. Atlas Antibodies
will handle the production, marketing and sales of the antibody products
developed and validated in the Human Proteome Resource (HPR) Center. The
Human Proteome Resource (HPR) Center is performing a systematic exploration
of the human proteome with Affinity (Antibody) based Proteomics, combining
high-throughput generation of affinity-purified (mono-specific) antibodies
with protein profiling using tissue microarrays. The Human Proteome
Resource (HPR) Center is located in Stockholm and Uppsala, Sweden and is
running the Swedish Human Protein Atlas (HPA) program. The HPA program
generates expression and localization patterns of proteins in a large
portion of both normal and cancer human tissues and organs resulting in the
antibody-based profiling presented in the publicly available Human Protein
Atlas (HPA) (
http://www.proteinatlas.org). The HPA vision is to enable the
systematic generation of quality assured antibodies to all non-redundant
human proteins and to use these reagents to functionally explore human
proteins, protein variants and protein interactions.
Cautionary Statement: This release contains forward-looking statements
relating to future performance, goals, strategic actions and initiatives
and similar intentions and beliefs and other statements regarding the
Companies' expectations, goals, beliefs, intentions and the like, which
involve assumptions regarding the Companies' operations and conditions in
the markets the Companies serve. The Companies do not undertake any
obligation to update these forward-looking statements.
'/>"/>SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend2.
Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies3.
Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth4.
Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge5.
Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 20076.
Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech7.
Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies8.
Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call9.
Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types10.
Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.11.
Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute